Benefit
Plegridy contains the active substance PEG-IFN-β-1a, which is a PEG conjugated form of glycosylated, recombinant IFN-β modified with a single, linear molecule of 20 kDa methoxy-PEG-O-2-methylpropionaldehyde (mPEG). Plegridy or PEG-IFN-β-1a was approved by FDA in 2014 for treatment of relapsing remitting multiple sclerosis (RRMS) in adult patients. Elevations of hepatic enzymes and liver injury have been observed with the use of plegridy. Patients should be checked for signs of hepatic damage and treatment should be stopped if icterus or other clinical symptoms of hepatic dysfunction appears.
